Characterization of AZD4694, a novel fluorinated Aβ plaque neuroimaging PET radioligand

Journal of Neurochemistry

Volumn 114, Issue 3, 2010, Pages 784-794

  Juréus, Anders ^a   Swahn, Britt Marie ^a   Sandell, Johan ^a   Jeppsson, Fredrik ^a   Johnson, Allan E ^a   Johnström, Peter ^a   Neelissen, Jan A M ^a   Sunnemark, Dan ^a   Farde, Lars ^a,b   Svensson, Samuel P S ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; amyloid; neuroimaging; positron emission tomography; Tg2576

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AZD 4694; BENZOFURAN DERIVATIVE; FLUORINE 18; FLUTEMETAMOL; RADIOLIGAND; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; FLUORINATED HYDROCARBON; FLUORINE; FLUORINE DERIVATIVE; FLUTAFURANOL;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; CONTROLLED STUDY; DRUG STRUCTURE; HALF LIFE TIME; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TRANSGENIC MOUSE; WHITE MATTER; AGED; AMYLOID PLAQUE; ANIMAL; BINDING COMPETITION; DIAGNOSTIC USE; FEMALE; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROCEDURES; RADIOASSAY; RAT; SCINTISCANNING; SPRAGUE DAWLEY RAT; VERY ELDERLY;

MUS; RATTUS;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BENZOFURANS; BINDING, COMPETITIVE; FEMALE; FLUORINE COMPOUNDS; FLUORINE RADIOISOTOPES; HUMANS; HYDROCARBONS, FLUORINATED; INJECTIONS, INTRAVENTRICULAR; MALE; MICE; MICE, TRANSGENIC; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 77954338544     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06812.x     Document Type: Article

References (32)

1. Aizenstein H. J., Nebes R. D., Saxton J. A. et al. (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol. 65, 1509 1517.
2. Andersson J., Varana K., Cselenyi Z. et al. (2010) Radiosynthesis of the candidate β-amyloid radioligand [11C]AZD2184: positron emission tomography examination and metabolite analysis in cynomolgus monkeys. Synapse (in press).
3. Bennett D. A., Schneider J. A., Wilson R. S., Bienias J. L. Arnold S. E. (2004) Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer's disease and level of cognitive function. Arch. Neurol. 61, 378 384.
4. Braak H. Braak E. (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. (Berl.) 82, 239 259.
5. Dickson D. W. (2005) Required techniques and useful molecular markers in the neuropathologic diagnosis of neurodegenerative diseases. Acta Neuropathol. (Berl.) 109, 14 24.
6. Fodero-Tavoletti M. T., Rowe C. C., McLean C. A., Leone L., Li Q.-X., Masters C. L., Cappai R. Villemagne V. L. (2009) Characterization of PIB binding to white matter in Alzheimer's disease and other dementias J. Nucl. Med. 50, 198 204.
7. Ikonomovic M. D., Klunk W. E., Abrahamson E. E. et al. (2008) Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 131, 1630 1645.
8. Johnson A. E., Jeppsson F., Sandell J., Wensbo D., Neelissen J. A., Juréus A., Ström P., Norman H., Farde L. Svensson S. P. S. (2009) AZD2184: a radioligand for sensitive detection of beta-amyloid deposits. J. Neurochem. 108, 1177 1186.
9. Klunk W. E. Mathis C. A. (2008) The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation Curr. Opin. Neurol. 21, 683 687.
10. Klunk W. E., Engler H., Nordberg A. et al. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann. Neurol. 55, 306 319.
11. Klunk W. E., Lopresti B. J., Ikonomovic M. D. et al. (2005) Binding of the positron emission tomography traces Pittsburgh compound-B reflects the amount of amyloid-β in Alzheimer's disease brain but nou in transgenic mouse brain. J. Neurosci. 25, 10598 10606.
12. Knopman D. S., Parisi J. E., Salviati A. et al. (2003) Neuropathology of cognitively normal elderly. J. Neuropathol. Exp. Neurol. 62, 1087 1095.
13. Lockhart A., Lamb J. R., Osredkar T., Sue L. I., Joyce J. N., Ye L., Libri V., Leppert D. Beach T. G. (2007) PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain 130, 2607 2615.
14. Lombardo F., Shalaeva M. Y., Tupper K. A. Gao F. (2001) ELogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds. J. Med. Chem. 44, 2490 2497.
15. Mathis C. A., Lopresti B. J., Mason N., Price J. C., Flatt N., Bi W., Ziolko S., DeKosky S. Klunk W. E. (2007a) Comparison of the amyloid imaging agents [F18]3′-FPIB and [C-11]PIB in Alzheimer's disease and control subjects. J. Nucl. Med. 48 (Suppl. 2 56.
16. Mathis C. A., Lopresti B. J. Klunk W. E. (2007b) Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl. Med. Biol. 34, 809 822.
17. Morris J. C., Roe C. M., Grant E. A., Head D., Storandt M., Goate A. M., Fagan A. M., Holtzman D. M. Mintun M. A. (2009) Pittsburgh Compound B imaging and prediction of pregression from cognitive normality to symptomatic Alzheimer Disease. Arch. Neurol. 66, 1469 1475.
18. Necula M., Kayed R., Milton S. Glabe C. G. (2007) Small molecule inhibitors of aggregation indicate that amyloid β oligomerization and fibrillization pathways are independent and distinct. J. Biol. Chem. 282, 10311 10324.
19. Nelissen N., Van Laere K., Thurfjell L., Owenius R., Vandenbulcke M., Koole M., Bormans G., Brooks D. J. Vandenberghe R. (2009) Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J. Nucl. Med. 50, 1251 1259.
20. Nelson P. T., Braak H. Markesbery W. R. (2009) Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J. Neuropathol. Exp. Neurol. 68, 1 14.
21. Nilsson M. R. (2004) Techniques to study amyloid fibril formation in vitro. Methods 34, 151 160.
22. 11C]AZD2184. Eur. J. Nucl. Med. Mol. Imaging 36, 1859 1863.
23. Pike K. E., Savage S., Villemange V. L., Ng S., Moss S. A., Maruff P., Mathis C. A., Klunk W. E., Masters C. L. Rowe C. C. (2007) β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130, 2837 2844.
24. Price J. L., Davis P. B., Morris J. C. White D. L. (1991) The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol. Aging 12, 295 312.
25. Price J. L., McKeel Jr. D. W., Buckles V. D. et al. (2009) Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurbiol. Aging 30, 1026 1036.
26. Rinne J. O., Brooks D. J., Rossor M. N. et al. (2010) (11)C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 9, 363 372.
27. Rosen R. F., Walker L. C. LeVine H. (2009) PIB binding in aged primate brain: enrichment of high-affinity sites in humans with Alzheimer's disease. Neurobiol. Aging. doi:.
28. 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Neurology 7, 129 135.
29. Sperling R. A., LaViolette P. S., O'Keefe K. et al. (2009) Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 63, 178 188.
30. Swahn B. M., Wensbo D., Sandell J. et al. (2010) Synthesis and evaluation of 2-pyridylbenzothiazole, 2-pyridyl-benzoxazole and 2-pyridylbenzofuran derivatives as 11C-PET imaging agents for β-amyloid plaques. Bioorg. Med. Chem. Lett. 20, 1976 1980.
31. Villemagne V. L., Pike K. E., Darby D. et al. (2008) Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 46, 1688 1697.
32. Yang F., Lim G. P., Begum A. N. et al. (2005) Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280, 5892 5901.